However, despite the biological plausibility of combination TBK1/MEK inhibition as an anticancer therapy, resistance to this regimen develops rapidly in mouse models of KRasG12DLbk1null and KRasG12DTrp53null lung cancers due to the epigenetic-mediated upregulation of IGF1 and YAP1 [235]. This evidence concerns the gene TBK1 and lung cancer.